Lakshmikumaran and Sridharan Attorneys Acted For Fleming Laboratories and Its Promoters In investment by healthcare focussed PE fund InvAscent
Lakshmikumaran and Sridharan Attorneys (LKS) acted for Fleming Laboratories Limited (FLL) and its promoters in a private
Lakshmikumaran and Sridharan Attorneys Acted For Fleming Laboratories and Its Promoters In investment by healthcare focussed PE fund InvAscent
Lakshmikumaran and Sridharan Attorneys (LKS) acted for Fleming Laboratories Limited (FLL) and its promoters in a private equity transaction of INR 1,100 million by India Life Sciences Fund IV (ILSF) for a minority stake in FLL.
LKS advised FLL and its promoters with deal structuring, drafting, and negotiations of the transaction documents and assisted in closure of the deal end to end.
LKS Corporate and M&A team involved in this transaction consisted of Noorul Hassan (Partner), Dinesh Babu Eedi (Associate Partner), Principal Associates Manan Chhabra and Kumar Panda.
“Hyderabad is a key region for pharmaceutical and life sciences sector, and we have been regularly advising companies in this space. We are happy to have assisted the promoters of Fleming in closing the deal. As investor interest continues to boom, we expect to witness more transactions in the region,” said Noorul Hassan.
Quillon Partners advised InvAscent on this investment deal. The transaction team of Quillon Partners was led by Namrata Sinha (Partner) and Adeeb Shah.
FLL is a homegrown active pharmaceutical ingredient (API) player, engaged in the business of manufacture and marketing of bulk drugs and intermediates. ILSF is a fund managed by InvAscent, a healthcare-focused private equity firm in India. FLL is planning to use the funds to expand its capacity by building its third manufacturing unit as well as for its foray into fermentation-based API manufacturing.